demonstrated that HER2 amplification was significantly more frequent in lymph node metastases (15.3%) than in matched primary bladder cancers as well as being more apparent in the luminal than in the basal subtypes [79]. This evidence concerns the gene ERBB2 and urinary bladder carcinoma.